Sickle Cell Disease Treatment Market -Global Industry Analysis and Forecast 2023 – 2029

Sickle Cell Disease Treatment Market was valued at US$ 3.36 Bn. in 2022. The Global Sickle Cell Disease Treatment Market is estimated to grow at a CAGR of 19.1 % over the forecast period.
Sickle Cell Disease Treatment Market Overview:
Sickle cell disease is a group of diseases that affect hemoglobin, the molecule responsible for transporting oxygen throughout the body's tissues and organs. The red blood cell takes on a sickle or crescent shape when this disease attacks and the patient becomes anemic. The most usual time for signs and symptoms of sickle cell disease to occur is during early childhood, and they last until puberty. When red blood cells take on a specific shape, they are more likely to break down prematurely, resulting in anemia.

To know about the Research Methodology :- Request Free Sample Report

The Sickle Cell Disease market analyses and forecasts the market size, in terms of value, for the market. Further, the Sickle Cell Disease Market is segmented by Treatment Modality, End-user, and Region. Based on Treatment Modality, the Sickle Cell Disease market is segmented under Blood Transfusion, Bone Marrow Transplant & Pharmacotherapy. Based on the end-user, the market is segmented under the Hospitals, Specialty Clinics & Others. The market sizing and forecasts have been done for each segment based on value (in USD Billion).
Sickle Cell Disease Treatment Market Dynamics:
Increasing SCD prevalence to drive market:

One of the primary factors forecast to boost the market's growth is the increased frequency of sickle cell disease, particularly in Africa. According to the United Nations, around 20-25 million individuals worldwide suffer from SCD. Also, Sub-Saharan Africa has the highest prevalence of sickle cell disease, with nearly 240,000 children diagnosed each year. According to the Centers for Conditions Control and Prevention, the disease affects one out of every 365 African-American babies born in the United States. As a result, the government is actively working to enhance sickle cell disease patients' access to care and diagnosis. This is expected to fuel the growth of the SCD Treatment market.

The robust pipeline is another factor driving the industry forward:

Strong pharmaceutical corporations with novel medicines in clinical trials, as well as mid and small pharmaceutical companies with early-stage pipeline products, make up the sickle cell disease pipeline. Because of the strong efficacy of these treatments in early clinical studies, regulatory agencies have given them a good view, assisting vendors with the rapid development of these drugs. The strong pipeline for the treatment of sickle cell disorders is also fueled by recent technological advancements and the detection of sickle cell disease.

Market growth through new product launches:

During the period 2022-2029, products including Zynteglo, CTX001, Mitapivat, and FT-4202 are forecasted to be approved. Fast track and priority review designations favor the release of certain medications. In Europe, for example, CTX001 has been given the EMA's priority medicines (PRIME) designation. This is expected to increase demand for the product.

Treatment at a High Cost to Slow Growth:

The high expense of therapy and sickle cell disease places a considerable financial strain on patients, health insurance companies, and government healthcare programs. A bone marrow transplant, which is advised in severe cases, costs between $100,000 and $500,000. The first-line medication for sickle cell disease, hydroxyurea, costs roughly USD 1,000-1,500 per year. Also, the cost of a blood transfusion is above $1,000 per year.

The high expense of sickle cell disease therapy has a significant impact on the number of patients who choose or have access to these treatments, particularly in impoverished and developing nations. Patients in high-income nations with a well-established payment structure make up the target population for approved medications and pipeline prospects. This is forecasted to slow the market's growth.

In rural areas, medications are limited:

The sickle cell disease treatment market in developing countries is forecasted to be hampered by the lack of medications in various tribal regions of India. The market is being hampered by corruption in drug sales and the low disposable income of the majority of sickle cell disease patients in countries.
Challenge: Treatment costs prohibit market growth

The market has recently accepted treatment solutions such as Siklos, Endari, and DROXIA. However, they are too expensive. Meanwhile, blood transfusion is the most popular therapy choice due to its therapeutic nature. This expensive treatment option, however, comes with an additional cost in the form of a hospital stay, which is required for such surgeries. Because most countries lack payment systems or patient assistance programs, a huge percentage of patients are faced with expensive drug expenses. The gene therapy programs now in development are forecast to be expensive, and the market will confront this problem during the forecast period.

Treatment for Illnesses Involving Blood Plasma:

Hemoglobin deficiency can cause a variety of health problems, and it is critical to treat sickle cell disease. Patients with low hemoglobin levels should seek therapy as soon as possible, according to doctors. This aspect is expected to propel the worldwide sickle cell disease therapy market forward in the coming years. Over the next several years, the worldwide sickle cell disease therapy market is expected to draw investments from new sources.
Sickle Cell Disease Treatment Market Trends:
Transfusion assistance remains an important intervention in the therapy of sickle cell disease patients, according to the American Society of Hematology's 2022 guidelines (SCD). Many issues associated with SCD are treated with red cell transfusions, both acutely and chronically. According to a report published in the HINDAWI journal in September 2021 titled "Current modalities of sickle cell disease management," there is growing interest in the role of transfusion therapy in the management of SCD, with over 50.0 % of SCD children receiving at least one or more of blood transfusions during their childhood. Plasma transfusion provides the potential for players in this field. A number of plasma transfusion trials for sickle cell treatment are currently underway in the United States, according to Clinicaltrials.gov (2021). For example, in December 2021, a study titled "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FTX-6058" was published for a Phase 1 multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics (PK), foetal hemoglobin (HbF) induction, and biological activity of FTX-6058 in sickle cell disease patients aged 18 to 65 years old (SCD). As a result, the blood transfusion market is forecast to increase rapidly over the forecast period.
Sickle Cell Disease Treatment Market Segment Analysis:
Based on Treatment Modality, The blood transfusion category dominated the global market in 2022, accounting for 67.1 % of total revenue. One of the most common consequences of SCD is stroke. According to the American Society of Hematology, about 11% of SCD patients experience clinically evident strokes before the age of 20. In SCD patients, blood transfusion treatment is an efficient strategy to avoid stroke occurrences. As a result, the significant use of blood transfusions is a key element in the segment's dominance.

During the forecast period, the pharmacotherapy segment is forecast to grow at a rapid pace. The government's substantial support for pharmaceutical businesses is responsible for the segment's rapid growth. Because there are few therapy alternatives on the market right now, the government promotes research through financing and classifications such as orphan pharmaceuticals, fast track, priority review, and others. This would hasten the entry of new pharmaceuticals into the market and provide the industry with a considerable boost in growth.

Based on End-user, The market is divided into hospitals, specialist clinics, and others based on the end-user in 2022, accounting for 32.1 % of the share. Throughout the forecast period, the hospital sector is forecasted to dominate the market. In the following years, this is forecast to promote the growth of the hospital segment. The specialized clinic segment is growing because of an increase in the number of clinics. Also, because SCD is linked to a variety of symptoms, outpatient visits are common. Another aspect contributing to the segment's growth is this. As a result of the growing number of patients who use drugs, home care is becoming more popular. This is likely to boost the other segment's growth.
Sickle Cell Disease Treatment Market Regional Insights:
The North America region held the largest market share accounting for 37.2% in 2022. The North America region is expected to witness significant growth at a CAGR of 11% through the forecast period, with the United States being the largest contributor. Improved access to SCD therapy and possible pipeline medications are credited with the region's growth. The United States' robust government support would further promote the market's healthy development. According to a study published in National Centers for Biotechnological Information, the National Heart, Lung, and Blood Institute (NHLBI) established the Cure Sickle Cell Initiative in 2021, a joint research endeavor aimed at speeding up the development of genetic medicines to cure SCD. In addition, roughly 1 in 12 African Americans has the autosomal recessive mutation, and 300,000 babies are born with sickle cell anemia each year. As a result of the aforementioned factors, the studied market in the region is forecast to develop.
Sickle Cell Treatment Market Competitive Landscape:
With various regional and worldwide firms present, the sickle cell treatment industry is fiercely competitive. In the market under investigation, companies are taking steps to develop novel remedies. Novartis AG, Global Blood Therapeutics Inc., Emmaus Medical Inc., Addmedica, Medunik USA Inc., and Bristol-Myers Squibb Company are some of the market's major participants.

The objective of the report is to present a comprehensive analysis of the global Sickle Cell Disease Treatment Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear, futuristic view of the industry to the decision-makers.

The reports also help in understanding the Sickle Cell Disease Treatment Market dynamic and structure by analyzing the market segments and projecting the Sickle Cell Disease Treatment Market size. Clear representation of competitive analysis of key players by Design, price, financial position, product portfolio, growth strategies, and regional presence in the Sickle Cell Disease Treatment Market make the report investor’s guide.
Sickle Cell Disease Treatment Market Scope: Inquiry Before Buying



Sickle Cell Disease Treatment Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2018 to 2022
Market Size in 2022:
US$ 3.36 Bn.


Forecast Period 2023 to 2029 CAGR:
19.1%
Market Size in 2029:
US$ 11.43 Bn.


 Segments Covered:
by Treatment Modality
Blood Transfusion
Bone Marrow Transplant
Pharmacotherapy
Hydroxyurea
Branded Drugs


by End-user
Hospitals
Specialty Clinics
Others


by Route of Administration
Oral
Parenteral


by Type
Sickle Cell Anemia
HbSC
Others



Sickle Cell Disease Treatment Market by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Sickle Cell Disease Treatment Market Key Players:
1. Novartis AG
2. Global Blood Therapeutics Inc.
3. Emmaus Medical Inc.
4. Addmedica
5. Medunik USA Inc.
6. Bristol-Myers Squibb Company
7. AstraZeneca Plc.
8. Eli Lilly and Company
9. Pfizer Inc.
10.Baxter International Inc.
11.Bluebird bio, Inc.
12.Sangamo Therapeutics, Inc.
13.Acceleron Pharma, Inc.
14.Arena Pharmaceuticals, Inc.
15.Alnylam Pharmaceuticals, Inc.
16.Merck & Co. Inc.
17.Sanofi
18.Gilead Sciences,
19.Johnson & Johnson
20.Mast Therapeutics

Frequently Asked Questions:

1] What is the forecasted market size and growth rate of the Global Sickle Cell Disease Treatment market?
Ans. Forecasted market size US$ 11.43 Bn. Till 2029, with a CAGR of 19.1 %.

4] What is the forecast period for the Global Sickle Cell Disease Treatment Market?
Ans. The forecast period for the Sickle Cell Disease Treatment Market is 2023-2029.

3] Which region is expected to hold the highest share in the global Sickle Cell Disease Treatment Market?
Ans. The North American region is expected to hold the highest share in the Sickle Cell Disease Treatment market.

4] Which are the leading key players in the global Sickle Cell Disease Treatment market?
Ans. Novartis AG, Global Blood Therapeutics Inc., Emmaus Medical Inc., Addmedica, Medunik USA Inc., Bristol-Myers Squibb Company, AstraZeneca Plc., Eli Lilly, and Company are some of the key players in the Sickle Cell Disease Treatment market.

5] What segments are covered in Global Sickle Cell Disease Treatment?
Ans. The Global Sickle Cell Disease Treatment Market is segmented into Treatment Modality, End-user, and Region.